Cassava Sciences announced the completion of another interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer’s disease. A routine, scheduled meeting of a Data and Safety Monitoring Board recommended that both of Cassava Sciences’ on-going Phase 3 studies continue as planned, without modification. The DSMB is composed of independent clinical research experts who periodically review interim patient safety data for Cassava Sciences’ on-going Phase 3 trials of simufilam in Alzheimer’s disease. This DSMB only reviews patient safety. It does not assess drug efficacy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA:
- Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
- Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
- Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
- Cassava: Internal investigation found no evidence to substantiate allegations
- Cassava Sciences sees 1H24 cash use for operations $35M-$45M
